The combination of bortezomib and resveratrol may prevent muscle wasting in diabetes.
Hypercatabolic syndrome is a biochemical state characterized by a imbalance between catabolism and anabolism in favor of catabolism. Diabetes is an example of hypercatabolic syndrome with presence of decreased insulin level or impaired insulin signaling besides increased inflammatory cytokines. One of the significant outcomes of this state is accelerated protein degradation and muscle wasting. Increased ubiquitin-proteasomal system activity is the major responsible for the muscle wasting. Increase in expression and activities of proteasomal proteins in diabetes had been determined. NF-κB transcription factor mediated inflammation and oxidative stress accompanies proteasomal activity increase. Oxidative stress continuously produces substrate for proteasomes by causing protein oxidation. An intervention that inhibits proteasomal activity, suppressing inflammation and oxidative stress may form a solution in order to prevent muscle wasting. Therefore, I am considering that the combined use of bortezomib, a proteasome inhibitor and an anti-inflammatory with resveratrol, an antioxidant and anti-inflammatory, could prevent diabetes induced muscle wasting. This combination may be a novel therapeutic approach for muscle wasting.
Department of Medical Biochemistry, Dokuz Eylül University Medical School, 35340 İnciraltı, İzmir, Turkey. halil.resmi@deu.edu.tr
Halil
H
Resmi
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000975:Antioxidants / Q000008:administration & dosage; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D048909:Diabetes Complications / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003921:Diabetes Mellitus, Experimental / Q000628:therapy; D006801:Humans; D007249:Inflammation; D008954:Models, Biological; D009133:Muscular Atrophy / Q000150:complications* / Q000517:prevention & control*; D011480:Protease Inhibitors / Q000008:administration & dosage; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D011719:Pyrazines / Q000008:administration & dosage*; D051381:Rats; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage*
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D013267:Stilbenes; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex; D000077185:Resveratrol